UCB SA (0NZT)

London
Currency in EUR
170.33
+4.94(+2.99%)
Real-time Data·
0NZT Scorecard
Full Analysis
Has a perfect Piotroski Score of 9
0NZT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
166.05170.33
52 wk Range
129.35198.70
Key Statistics
Edit
Bid/Ask
168.40 / 171.95
Prev. Close
165.38
Open
166.05
Day's Range
166.05-170.33
52 wk Range
129.35-198.7
Volume
609
Average Volume (3m)
106.4K
1-Year Change
19.58%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
0NZT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 16 consecutive years

UCB SA News & Analysis

Show more

UCB SA Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; UCB0222 for the treatment of Parkinson’s disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Employees
9215

Compare 0NZT to Peers and Sector

Metrics to compare
0NZT
Peers
Sector
Relationship
P/E Ratio
29.2x27.7x−0.5x
PEG Ratio
0.140.410.00
Price/Book
3.1x2.6x2.6x
Price / LTM Sales
5.1x2.7x3.0x
Upside (Analyst Target)
-36.2%50.5%
Fair Value Upside
Unlock11.3%7.5%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.61%
Dividend Yield
0.58%
Industry Median 2.53%
Annualised payout
0.97
Paid annually
5-Years Growth
+2.31%
Growth Streak

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / 1.98B
EPS Revisions
Last 90 days

0NZT Income Statement

FAQ

What Is the UCB SA (0NZT) Stock Price Today?

The UCB SA stock price today is 170.33.

What Stock Exchange Does UCB SA Trade On?

UCB SA is listed and trades on the London Stock Exchange stock exchange.

What Is the Stock Symbol for UCB SA?

The stock symbol for UCB SA is "0NZT."

Does UCB SA Pay Dividends? What’s The Current Dividend Yield?

The UCB SA dividend yield is 0.58%.

What Is the UCB SA Market Cap?

As of today, UCB SA market cap is 32.32B.

What Is UCB SA's Earnings Per Share (TTM)?

The UCB SA EPS (TTM) is 5.61.

When Is the Next UCB SA Earnings Date?

UCB SA will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is 0NZT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has UCB SA Stock Split?

UCB SA has split 0 times.

How Many Employees Does UCB SA Have?

UCB SA has 9215 employees.

What is the current trading status of UCB SA (0NZT)?

As of 25 Jun 2025, UCB SA (0NZT) is trading at a price of 170.33, with a previous close of 165.38. The stock has fluctuated within a day range of 166.05 to 170.33, while its 52-week range spans from 129.35 to 198.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.